ASH tackles COVID-19 with hematology-related FAQ, promotes new registriesApril 14, 2020COVID-19 UpdatesMultiple MyelomaMyelodysplastic Syndrome
First report of MM patient successfully treated for COVID-19 with tocilizumabApril 6, 2020COVID-19 UpdatesMultiple MyelomaOncology
Maintaining cancer care in the face of COVID-19April 1, 2020COVID-19 UpdatesGenitourinary CancerLung CancerMultiple MyelomaMelanomaInfectious DiseasesOncology
New CAR T-cell therapy eliminates MM and tumor propagating cells without fratricide in lab studyFebruary 26, 2020Multiple MyelomaOncology
Myeloma patients over age 70 can benefit from auto-HC transplantDecember 7, 2019Multiple MyelomaOncologyRare Diseases
Bispecific CAR T-cells yield high response rate in relapsed/refractory myelomaDecember 7, 2019Multiple MyelomaOncologyImmuno-oncology
High complete response rate seen with novel CAR-T for myelomaDecember 7, 2019Multiple MyelomaImmuno-oncologyOncologyRare Diseases
ASH preview: Key themes include tackling CAR T obstacles, sickle cell advances, VTENovember 26, 2019Multiple MyelomaImmuno-oncologyOncology
Early lenalidomide may delay progression of smoldering myelomaNovember 19, 2019Multiple MyelomaOncology
Levofloxacin prophylaxis improves survival in newly diagnosed myelomaNovember 1, 2019Multiple MyelomaHematologic Malignancies
SC daratumumab deemed feasible for every multiple myeloma patientJuly 11, 2019Multiple MyelomaHematologic Malignancies
Recombinant vaccine cut herpes zoster rate in immunocompromised patientsJuly 9, 2019VaccinesInfectious DiseasesMultiple MyelomaHematologic Malignancies
FDA approves Xpovio for relapsed/refractory multiple myelomaJuly 3, 2019Multiple MyelomaHematologic Malignancies
